Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the complete record of transactions filed by Ellingson Rachel, Directeur de la Stratégie. Director active across 2 companies, notably Zimmer Biomet Holdings, INC.. In total, 17 filings have been published. Activity tracked since 1 May 2021. The latest transaction was disclosed on 20 February 2025 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
17 of 17 declarations
Ellingson Rachel is Director de la Stratégie. She is associated with Biolife Solutions INC, where she is Director, and with Zimmer Biomet Holdings, INC., where she is Chief Administrative Officer. The record shows 17 filings in total, and the recent filings observed run from 2021-05-03 to 2026-02-26. The buy and sell volumes shown for this recent sample are 0 EUR each, and the most frequent transaction nature is Attribution.